Oclacitinib: Veterinary Guide for Allergic Dermatitis

Known as original brand(s)

Apoquel

Oclacitinib is an innovative veterinary antipruritic and anti-inflammatory agent belonging to the class of selective Janus Kinase (JAK) inhibitors. Administered as oclacitinib maleate, it is specifically developed for dermatological use in veterinary medicine and serves as a highly effective alternative to glucocorticoids and ciclosporin for managing allergic dermatitis in dogs.

The mechanism of action of oclacitinib involves selective inhibition of JAK1 and JAK3 enzyme activity. The drug inhibits the functions of various pro-inflammatory, pro-allergic, and pruritogenic (itch-inducing) cytokines that are dependent on JAK enzyme activity (specifically interleukins IL-31, IL-2, IL-4, IL-6, and IL-13). Rapid suppression of IL-31 interrupts the itch sensation as early as 4 hours after oral administration.

Clinical use of oclacitinib provides rapid relief from itching, reduces cutaneous inflammation, prevents self-trauma caused by scratching, and significantly improves the quality of life for allergic dogs and their owners.

Wikipedia page
Oclacitinib

Indications

Oclacitinib is indicated in veterinary dermatology for the following applications:

  • Atopic Dermatitis: Control of clinical manifestations of atopic dermatitis in dogs (chronic allergic itch and skin inflammation).
  • Allergic Dermatitis: Control of pruritus associated with allergic dermatitis of various etiologies (flea allergy dermatitis, food allergy, contact dermatitis).
  • Symptomatic Relief: Rapid reduction of pruritus and associated skin lesions in acute and chronic allergic flare-ups.

Dosage and administration

Oclacitinib is intended strictly for oral administration in dogs. The treatment schedule consists of two phases:

  • Recommended Dosage: The initial therapeutic dose is 0.4 to 0.6 mg oclacitinib per kg body weight.
  • Dosing Regimen: Administered twice daily (every 12 hours) for the first 14 days of treatment. Thereafter, a maintenance dose of once daily (every 24 hours) is administered.
  • Administration Method: Tablets are given orally and may be administered with or without food.
  • Duration of Treatment: Duration is determined by the attending veterinarian based on clinical response and disease severity (suitable for long-term maintenance therapy).

Oclacitinib is contraindicated in the following cases:

  • Age and Weight: Dogs less than 12 months of age or weighing less than 3 kg (6.6 lbs).
  • Infections and Demodicosis: Presence of severe active infections, generalized demodicosis, or severe mucocutaneous candidiasis.
  • Neoplasia: Evidence of malignant neoplasia or history of immunosuppression-sensitive cancers.
  • Breeding and Lactation: Do not use in breeding dogs, or in pregnant or lactating bitches.
  • Hypersensitivity: Known hypersensitivity to oclacitinib or any of the formulation excipients.

Oclacitinib exhibits a favorable safety profile, but the following adverse reactions may occasionally occur:

  • Gastrointestinal System: Diarrhea, vomiting, nausea, and temporary loss of appetite (often transient).
  • Systemic Symptoms: Lethargy, apathy, and mild weight gain during prolonged use.
  • Dermatological and Infectious: Development of secondary bacterial or fungal skin infections, pododermatitis, or histiocytomas/papillomas.
  • Laboratory Alterations: Transient decrease in leukocyte counts (neutropenia), anemia, or minor elevations in liver enzymes and serum cholesterol.

Frequently Asked Questions

Oclacitinib (widely known by the brand name Apoquel) is an innovative veterinary medication belonging to the Janus kinase (JAK) inhibitor class. It selectively inhibits Janus kinase enzymes (primarily JAK1), which play a pivotal role in mediating cytokine-driven signals responsible for pruritus, allergic responses, and inflammation. Unlike traditional steroid treatments, oclacitinib acts specifically by interrupting the pathway that triggers the urge to scratch, providing rapid relief within hours of the initial dose.
Oclacitinib is indicated for the control of pruritus associated with allergic dermatitis, as well as for the management of atopic dermatitis in dogs. The medication effectively alleviates both seasonal and non-seasonal allergic flares triggered by flea infestations, food sensitivities, or environmental allergens such as dust mites and pollens. By stopping the persistent itch-scratch cycle, it prevents secondary skin infections and markedly improves the animal's quality of life.
Oclacitinib is available as scored tablets in multiple strengths (3.1 mg, 5.4 mg, and 16 mg). The treatment regimen follows a two-phase protocol: for the first 14 days of therapy, the drug is administered orally twice daily at a target dose of approximately 0.4 to 0.6 mg per kilogram of body weight to rapidly control acute pruritus. From Day 15 onward, therapy transitions to a maintenance schedule where the same individual dose is given only once daily. Tablets may be administered with or without food.
Oclacitinib is formulated exclusively for canine use and carries specific restrictions. It must not be administered to dogs younger than 12 months of age, as developing immune systems in puppies are more susceptible to infections. Furthermore, the drug is contraindicated in pregnant or lactating females, as well as dogs intended for breeding. It should be used with caution in patients with concurrent serious infections, active malignancies, or compromised immune systems.
Oclacitinib is generally well-tolerated by dogs, but adverse effects may occasionally appear during prolonged use. These can include mild lethargy, vomiting, diarrhea, decreased appetite, or weight gain. Because the mechanism involves modulating immune pathways, some treated animals may exhibit an increased susceptibility to secondary infections, such as skin pyoderma, urinary tract infections, or papillomas. Any emerging signs of illness or changes in the dog's condition should prompt a veterinary evaluation.

List of medicines by active substance

-9%
Octinib 5.4
View
Zenex Animal Health

Octinib 5.4

Oclacitinib
5.4 mg 20 tablets
1049₴ 1149₴
-8%
Octinib 16
View
Zenex Animal Health

Octinib 16

Oclacitinib
16 mg 20 tablets
1149₴ 1249₴
✅ All products loaded (2)
Unifarm

Unifarm app

Safari → Share → Add to Home Screen Firefox: menu ⋮ → Install or Add to Home screen. If missing, open the site in Chrome. Chrome: menu ⋮ → Install app or Add to Home screen.

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00